Overview
- Weekend reports from the Financial Times and other outlets said AstraZeneca had held preliminary merger talks with Bristol Myers Squibb that could create a near $400 billion company.
- A senior source told Reuters on Wednesday that there are no discussions and there never were talks between the two firms, and both companies declined to comment.
- The initial reports sent AstraZeneca shares sharply lower and pushed Bristol Myers stock higher before markets partially recovered after the Reuters denial.
- Analysts remain split on deal logic because AstraZeneca has a strong late‑stage pipeline while Bristol Myers faces major revenue risk from Eliquis and Opdivo losing exclusivity around 2028.
- Regulatory and disclosure issues would complicate any transaction since overlapping oncology drugs would draw U.S. antitrust scrutiny and U.K. market‑abuse rules would have required formal disclosure of talks.